MedTrace Logo

Lowering Events in Non-proliferative Retinopathy in Scotland

NCT03439345 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1151

Last updated 2025-05-14

Study results available
· View outcomes & findings →

Summary

LENS is a streamlined multicentre randomised placebo-controlled parallel-group trial investigating the effect of fenofibrate treatment on the progression of diabetic retinopathy/maculopathy.

Conditions

Interventions

DRUG

Fenofibrate 145 mg

One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

DRUG

Placebo Oral Tablet

One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • University of Glasgow

    collaborator OTHER

  • University of Aberdeen

    collaborator OTHER

  • University of Dundee

    collaborator OTHER

  • University of Edinburgh

    collaborator OTHER

  • NHS Scotland Diabetic Retinopathy Screening Collaborative

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • David Preiss, PhD FRCPath · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2023-11-17
Completion
2024-02-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03439345 on ClinicalTrials.gov